FDA — authorised 17 August 2017
- Application: NDA208558
- Marketing authorisation holder: ASTRAZENECA
- Local brand name: LYNPARZA
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Olaparib 200-300 mg BID, daily in United States
FDA authorised Olaparib 200-300 mg BID, daily on 17 August 2017
Marketing authorisation
Other Oncology approved in United States
Frequently asked questions
Is Olaparib 200-300 mg BID, daily approved in United States?
Yes. FDA authorised it on 17 August 2017.
Who is the marketing authorisation holder for Olaparib 200-300 mg BID, daily in United States?
ASTRAZENECA holds the US marketing authorisation.